1. Home
  2. ALLO vs BAND Comparison

ALLO vs BAND Comparison

Compare ALLO & BAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • BAND
  • Stock Information
  • Founded
  • ALLO 2017
  • BAND 2000
  • Country
  • ALLO United States
  • BAND United States
  • Employees
  • ALLO N/A
  • BAND N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • BAND Computer Software: Prepackaged Software
  • Sector
  • ALLO Health Care
  • BAND Technology
  • Exchange
  • ALLO Nasdaq
  • BAND Nasdaq
  • Market Cap
  • ALLO 371.8M
  • BAND 358.3M
  • IPO Year
  • ALLO 2018
  • BAND 2017
  • Fundamental
  • Price
  • ALLO $1.11
  • BAND $13.71
  • Analyst Decision
  • ALLO Strong Buy
  • BAND Hold
  • Analyst Count
  • ALLO 10
  • BAND 5
  • Target Price
  • ALLO $8.90
  • BAND $21.00
  • AVG Volume (30 Days)
  • ALLO 4.1M
  • BAND 262.1K
  • Earning Date
  • ALLO 05-13-2025
  • BAND 05-07-2025
  • Dividend Yield
  • ALLO N/A
  • BAND N/A
  • EPS Growth
  • ALLO N/A
  • BAND N/A
  • EPS
  • ALLO N/A
  • BAND N/A
  • Revenue
  • ALLO N/A
  • BAND $751,695,000.00
  • Revenue This Year
  • ALLO N/A
  • BAND $2.35
  • Revenue Next Year
  • ALLO $9.07
  • BAND $12.94
  • P/E Ratio
  • ALLO N/A
  • BAND N/A
  • Revenue Growth
  • ALLO N/A
  • BAND 18.51
  • 52 Week Low
  • ALLO $0.86
  • BAND $11.33
  • 52 Week High
  • ALLO $3.78
  • BAND $23.90
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 38.30
  • BAND 51.71
  • Support Level
  • ALLO $1.07
  • BAND $14.22
  • Resistance Level
  • ALLO $1.15
  • BAND $14.75
  • Average True Range (ATR)
  • ALLO 0.14
  • BAND 0.50
  • MACD
  • ALLO -0.01
  • BAND 0.11
  • Stochastic Oscillator
  • ALLO 27.17
  • BAND 57.98

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About BAND Bandwidth Inc.

Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of our revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.

Share on Social Networks: